Pfizer (PFE) recently announced that the U.S. Food and Drug Administration accepted the New Drug Application for ...

Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Pfizer delivered a strong Q2 earnings beat, raising FY2025 guidance and demonstrating effective cost-cutting. Learn why PFE ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer Inc. (NYSE:PFE) reported in its fiscal Q1 2025 results that the first phase of its manufacturing optimization program ...

Pfizer Inc (NYSE: PFE) saw its shares rise by more than 4% after the company reported strong second-quarter results that ...

Now, it’s worth noting Stock Advisor’s total average return is 1,019% — a market-crushing outperformance compared to 178 % ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

The American multinational biotech firm developed a form of santonin used to treat intestinal worms, which gained rapid ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.